InvestorsHub Logo
Followers 52
Posts 3317
Boards Moderated 0
Alias Born 10/26/2013

Re: antihama post# 1538

Saturday, 11/05/2016 8:49:51 AM

Saturday, November 05, 2016 8:49:51 AM

Post# of 3283
Mystery solved in where Seeking Alpha and others were getting 33.4M in revenues. When you click on the PR off the Yahoo website

http://finance.yahoo.com/news/spectrum-pharmaceuticals-provides-third-quarter-200500385.html

the PR doesn't mention what you find in this link

http://investor.sppirx.com/releasedetail.cfm?ReleaseID=997577

Financial Update: Q3 revenues were $33.4 million, including $30.3 million in product sales, with recently launched drug EVOMELA® (melphalan) for injection contributing $5.9 million. The Company ended the quarter with Cash and Cash Equivalents of $171.9 million.
Earnings Call Update: Spectrum is re-examining the accounting treatment of the 2013 acquisition of the rights to CE Melphalan from Ligand Pharmaceuticals. This re-examination is not expected to impact reported revenue or cash balance for this or prior periods. The previously scheduled earnings conference call for the third quarter 2016 will not take place today and the Company plans to release full financial results as soon as possible.
ROLONTISTM (eflapegrastim): The Company received conditional acceptance of ROLONTIS as the trade name for SPI-2012 from the FDA. The pivotal Phase 3 study is actively enrolling breast cancer patients. The Company is initiating an additional Phase 3 study to enroll patients primarily in Europe. Spectrum continues to expect to file a BLA in 2018.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SPPI News